Abstract
We evaluated the cost-effectiveness of Tisagenlecleucel (CD19CAR-T cells) versus salvage chemotherapy followed by hematopoietic cell transplantation in treating diffuse large b-cell lymphoma (DLBCL) patients who are refractory or relapsed after 2 or more lines of therapy from the US societal perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
